Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells

被引:97
作者
Bancos, Simona [1 ]
Bernard, Matthew P. [1 ]
Topham, David J. [2 ]
Phipps, Richard P. [1 ]
机构
[1] Univ Rochester, Dept Environm Med, Sch Med & Dent, Lung Biol & Dis Program, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY 14642 USA
关键词
Human B lymphocytes; Cox-2; NSAIDs; Antibody; HUMAN B-LYMPHOCYTES; CYCLOOXYGENASE-2; INHIBITION; WHOLE-BLOOD; ACETAMINOPHEN; ASPIRIN; INDUCTION; TRIAL; SELECTIVITY; ACTIVATION; PREVENTION;
D O I
10.1016/j.cellimm.2009.03.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The widely used non-steroidal anti-inflammatory drugs (NSAIDs) function mainly through inhibition of cyclooxygenases 1 and 2 (Cox-1 and Cox-2). Unlike Cox-1, Cox-2 is considered an inducible and proinflammatory enzyme. We previously reported that Cox-2 is upregulated in activated human B lymphocytes and using Cox-2 selective inhibitors that Cox-2 is required for optimal antibody synthesis. It is not known whether commonly used non-prescription and non-Cox-2 selective drugs also influence antibody synthesis. Herein, we tested a variety of Cox-1/Cox-2 non-selective NSAIDs, namely ibuprolfen, tylenol, aspirin and naproxen and report that they blunt IgM and IgG synthesis in stimulated human peripheral blood mononuclear cells (PBMC). Ibuprofen had its most profound effects in inhibiting human PBMCs and purified B lymphocyte IgM and IgG synthesis when administered in the first few days after activation. As shown by viability assays, ibuprofen did not kill B cells. The implications of this research are that the use of widely available NSAIDs after infection or vaccination may lower host defense. This may be especially true for the elderly who respond poorly to vaccines and heavily use NSAIDs. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:18 / 28
页数:11
相关论文
共 38 条
[1]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[2]   CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: Implications for adjuvant activity and antibody production [J].
Bernard, Matthew P. ;
Phipps, Richard P. .
CLINICAL IMMUNOLOGY, 2007, 125 (02) :138-148
[3]   Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use [J].
Blain, H ;
Boileau, C ;
Lapicque, F ;
Nédélec, E ;
Loeuille, D ;
Guillaume, C ;
Gaucher, A ;
Jeandel, C ;
Netter, P ;
Jouzeau, JY .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (03) :255-265
[4]   Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism [J].
Borthwick, Gillian M. ;
Johnson, A. Sarah ;
Partington, Matthew ;
Burn, John ;
Wilson, Robert ;
Arthur, Helen M. .
FASEB JOURNAL, 2006, 20 (12) :2009-2016
[5]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[6]   Pharmacodynamic of cyclooxygenase inhibitors in humans [J].
Capone, Marta L. ;
Tacconelli, Stefania ;
Di Francesco, Luigia ;
Sacchetti, Andrea ;
Sciulli, Maria G. ;
Patrignani, Paola .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2007, 82 (1-4) :85-94
[7]   Utilisation pattern of nonspecific nonsteroidal anti-inflammatory drugs and COX-2 inhibitors in a local health service unit in northeast Italy [J].
Chiroli, S ;
Chinellato, A ;
Didoni, G ;
Mazzi, S ;
Lucioni, C .
CLINICAL DRUG INVESTIGATION, 2003, 23 (11) :751-760
[8]   Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs [J].
Cryer, B ;
Feldman, M .
AMERICAN JOURNAL OF MEDICINE, 1998, 104 (05) :413-421
[9]  
CRYER FB, 1998, AM J MED, V105, pS20
[10]   National trends in cyclooxygenase-2 inhibitor use since market release - Nonselective diffusion of a selectively cost-effective innovation [J].
Dai, CL ;
Stafford, RS ;
Alexander, C .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (02) :171-177